DrugBiological
Secukinumab clinical trials
Also written AIN457, Cosentyx and AIN457A.
- studies test it
- 175
- open now
- 16
- in phase 3
- 82
- first study started
- 2005
Keep track of what changes. Save the secukinumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Cosentyx
- 23
Combined with it in one product
Studies by the year they started
175 studies that test it; most in 2016 (19)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 8 |
| 2010 | 9 |
| 2011 | 11 |
| 2012 | 10 |
| 2013 | 9 |
| 2014 | 8 |
| 2015 | 14 |
| 2016 | 19 |
| 2017 | 11 |
| 2018 | 7 |
| 2019 | 10 |
| 2020 | 15 |
| 2021 | 10 |
| 2022 | 6 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 45
- Phase 3
- 82
- Phase 4
- 35
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 125 · Other 50
Novartis Pharmaceuticals (121) · University of Erlangen-Nürnberg Medical School (3) · Taizhou Mabtech Pharmaceutical Co.,Ltd (2) · Assistance Publique - Hôpitaux de Paris (2) · University Hospital, Ghent (2) · University of California, San Francisco (2) · Icahn School of Medicine at Mount Sinai (2) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2)
Often tested with
Tested in the same studies.
Adalimumab (7) · Ustekinumab (7) · Ixekizumab (7) · Guselkumab (5) · Upadacitinib (4) · Tofacitinib (4) · Canakinumab (4) · Etanercept (4)
Studies
Open first, then newest update. How each study uses secukinumab is read from its arms, and is right about nine times in ten.
Testing it · 175
- A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial SpondyloarthritisNot yet recruitingPhase 4The University of Texas Health Science Center, HoustonNCT07770646Written as Secukinumab (IL-17i )
- Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).RecruitingPhase 1Novartis PharmaceuticalsNCT06751238Written as Secukinumab
- Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaRecruitingPhase 4Novartis PharmaceuticalsNCT07489573Written as Secukinumab
- Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular DiseaseNot yet recruitingPhase 4Peking University Third HospitalNCT07704190Written as Secukinumab (75 mg)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Secukinumab
- IL-17 Blockade to Decrease irAEs (REPLAY)RecruitingPhase 1Duke UniversityNCT07237594Written as Secukinumab Injection
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Secukinumab
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu PatientsNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07477795Written as Secukinumab
- Proactive TDM Versus Standard Use of Biologics in PsoriasisRecruitingPhase 4University Hospital, GhentNCT06398106Written as Proactive TDM-based dosing of secukinumab
- A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing SpondylitisRecruitingPhase 4Tongji HospitalNCT05303285Written as Secukinumab 300mg s.c.
- Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing SpondylitisNot yet recruitingPhase 4The Affiliated Hospital Of Guizhou Medical UniversityNCT06833112Written as Secukinumab
- A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese PatientsRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06707246Written as Secukinumab 300 MG; Tofacitinib 11mg
- Immunoclassification of Psoriasis: a Strategy for Precision MedicineRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05503875Written as adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
- Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisRecruitingPhase 4University of AthensNCT02144857Written as Secukinumab
- Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque PsoriasisNot yet recruitingPhase 4Singapore General HospitalNCT04239859Written as secukinumab
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as Secukinumab
- Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy VolunteersCompletedPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT07254325Written as Secukinumab 150mg s.c.
- Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT06331312Written as Secukinumab
- A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved RemissionActive, not recruitingPhase 4Novartis PharmaceuticalsNCT05622708Written as Secukinumab
- Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis SuppurativaCompletedPhase 3Novartis PharmaceuticalsNCT04179175Written as secukinumab
See all 175 studies that test secukinumab →
Given in every arm · 6 — secukinumab is usual care beside what is tested
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese PatientsNot yet recruitingPhase 4Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07485764Written as Secukinumab 300mg s.c.
- Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromeCompletedPhase 4Novartis PharmaceuticalsNCT03440736Written as Secukinumab
- A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4CompletedPhase 1Janssen Research & Development, LLCNCT05522517Written as Cosentyx
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic ArthritisCompletedPhase 2Novartis PharmaceuticalsNCT01169844Written as AIN457A
- Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque PsoriasisStatus unknownEarly Phase 1Guangdong Provincial Hospital of Traditional Chinese MedicineNCT04414605Written as Secukinumab Auto-Injector [Cosentyx]
- Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)CompletedPhase 3Novartis PharmaceuticalsNCT01350804Written as AIN457
As the comparator · 11 — what is tested is compared with secukinumab
- A Study to Evaluate the Efficacy and Safety of LZM012RecruitingPhase 3Livzon Pharmaceutical Group Inc.NCT06110676Written as Secukinumab
- Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Taizhou Mabtech Pharmaceutical Co.,LtdNCT06398652Written as Secukinumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3UCB Biopharma SRLNCT03536884Written as Secukinumab
- A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody TherapyActive, not recruitingPhase 3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT06945107Written as Secukinumab
- Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis PatientsCompletedPhase 3Bio-Thera SolutionsNCT05377944Written as EU-approved Cosentyx
- Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy SubjectsCompletedPhase 1Bio-Thera SolutionsNCT04711343Written as Cosentyx (US-licensed)
- A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe PsoriasisCompletedPhase 2Bond Avillion 2 Development LPNCT03384745Written as Secukinumab
- Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque PsoriasisCompletedPhase 3AbbVieNCT03478787Written as secukinumab
- A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)CompletedPhase 3Eli Lilly and CompanyNCT03535194Written as Secukinumab
- Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in PsoriasisCompletedPhase 1Novartis PharmaceuticalsNCT01828086Written as Secukinumab
- A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type PsoriasisCompletedPhase 3Janssen Research & Development, LLCNCT03090100Written as Secukinumab
Codes
What other systems call secukinumab · ClinicalTrials.gg INT005770
- MeSH (NLM) C555450secukinumabConfirmed NLM, Wikidata
- UNII (FDA) DLG4EML025SECUKINUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1599788Confirmed FDA, Wikidata
- Wikidata Q7444755secukinumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152315SecukinumabOne source FDA
- DrugBank DB09029One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C555450 | secukinumab | Confirmed NLM, Wikidata |
| UNII (FDA) | DLG4EML025 | SECUKINUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1599788 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7444755 | secukinumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152315 | Secukinumab | One source FDA |
| DrugBank | DB09029 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.